Organon & Co. (NYSE:OGN) Shares Sold by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. decreased its position in Organon & Co. (NYSE:OGN) by 66.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 305,348 shares of the company’s stock after selling 597,679 shares during the period. Jacobs Levy Equity Management Inc. owned approximately 0.12% of Organon & Co. worth $5,741,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. SG Americas Securities LLC increased its holdings in shares of Organon & Co. by 258.0% during the fourth quarter. SG Americas Securities LLC now owns 60,514 shares of the company’s stock valued at $873,000 after purchasing an additional 43,613 shares during the period. Raymond James Financial Services Advisors Inc. lifted its stake in shares of Organon & Co. by 39.1% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 115,213 shares of the company’s stock worth $1,661,000 after acquiring an additional 32,413 shares during the period. SeaCrest Wealth Management LLC bought a new position in shares of Organon & Co. in the fourth quarter valued at approximately $274,000. State of Alaska Department of Revenue increased its stake in shares of Organon & Co. by 417.8% during the fourth quarter. State of Alaska Department of Revenue now owns 157,249 shares of the company’s stock valued at $2,267,000 after acquiring an additional 126,882 shares during the period. Finally, Ballentine Partners LLC bought a new stake in Organon & Co. during the fourth quarter worth approximately $239,000. Institutional investors and hedge funds own 77.43% of the company’s stock.

Analyst Upgrades and Downgrades

OGN has been the topic of a number of research analyst reports. Piper Sandler lifted their target price on Organon & Co. from $22.00 to $24.00 and gave the stock an “overweight” rating in a report on Monday, April 29th. The Goldman Sachs Group boosted their target price on shares of Organon & Co. from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd.

Organon & Co. Stock Down 0.9 %

Shares of OGN stock traded down $0.21 during trading on Tuesday, hitting $22.27. 1,301,176 shares of the company were exchanged, compared to its average volume of 2,258,113. The business’s 50-day simple moving average is $20.88 and its 200 day simple moving average is $19.08. Organon & Co. has a twelve month low of $10.84 and a twelve month high of $24.08. The firm has a market capitalization of $5.73 billion, a price-to-earnings ratio of 5.50, a P/E/G ratio of 1.02 and a beta of 0.85. The company has a debt-to-equity ratio of 181.35, a quick ratio of 1.15 and a current ratio of 1.65.

Organon & Co. (NYSE:OGN) last released its earnings results on Thursday, May 2nd. The company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.31. Organon & Co. had a net margin of 16.50% and a negative return on equity of 360.57%. The company had revenue of $1.62 billion during the quarter, compared to the consensus estimate of $1.57 billion. As a group, analysts forecast that Organon & Co. will post 4.29 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, June 13th. Stockholders of record on Monday, May 13th were issued a dividend of $0.28 per share. The ex-dividend date of this dividend was Friday, May 10th. This represents a $1.12 annualized dividend and a dividend yield of 5.03%. Organon & Co.’s dividend payout ratio is 27.38%.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.